OVARIC
Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial
Cascales Campos Pedro Antonio, MD, PHD, Gonzalez Gil Alida, MD, PHD, Gil Gomez Elena, MD, PH1,Gonzalez Sanchez Rocio, PHD, Martınez Garcia Jeronimo, MD, PHD, Alonso Romero Jose Luis, MD, PHD, Nieto Diaz Anibal, MD, PHD, Barcelo Valcarcel Francisco, MD, PHD, Gomez Ruiz Alvaro Jesus, MD, PHD,Ramirez Romero Pablo, MD, PHD, and Gil Martinez Jose, MD, PHD
Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
Ziying Lei, MD; Yue Wang, MD; Jiahong Wang, MD; Ke Wang, MD; Jun Tian, MD; Ying Zhao, MD; Lipai Chen, MD; Jin Wang, MD; Jiali Luo, PhD; Manman Jia, MD;Hongsheng Tang, MD; Qingjun He, MD; Quanxing Liao, MD; Xiansheng Yang, MD; Tianpei Guan, MD; Li Wang, MD; Shuzhong Cui, MD, PhD;
The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
Guyu Zhang, Yimin Zhu, Chongdong Liu, Guangming Chao, Ran Cui and Zhenyu Zhang
Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis
Se Ik Kim, MD, Jaehyun Cho, MD, Eun Ji Lee, MD, Sunwoo Park, BS, Soo Jin Park, MDa,Aeran Seol, MD, Nara Lee, MD, Ga Won Yim, MD, PhD, Maria Lee, MD, PhD, Whasun Lim, PhD,Gwonhwa Song, PhD, Suk Joon Chang, MD, PhD, Jae Won Kim, MD, PhD, Hee Seung Kim, MD, PhD
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy
Stephanie L.Lima, Laura J.Havrilesky, Ashraf S.Habib, Angeles Alvarez Secord
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial
Simone N. Koole, MD; Christiaan van Lieshout, MSc; Willemien J. van Driel, PhD, MD; Evi van Schagen, MSc;Karolina Sikorska, PhD; Jacobien M. Kieffer, PhD; Jules H. Schagen van Leeuwen, MD, PhD; Henk W.R. Schreuder, MD, PhD;Ralph H. Hermans, MD, PhD; Ignace H. de Hingh, MD, PhD; Jacobus van der Velden, PhD, MD; Henriette J. Arts, MD, PhD;Leon F.A.G. Massuger, MD, PhD; Arend G. Aalbers, MD; Victor J. Verwaal, MD, PhD; Koen K. Van de Vijver, MD, PhD;Neil K. Aaronson, PhD; Harm van Tinteren, PhD; Gabe S. Sonke, MD, PhD; Wim H. van Harten, MD, PhD;andValesca P. Ret`el, PhD
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
W.J. van Driel, S.N. Koole, K. Sikorska, J.H. Schagen van Leeuwen, H.W.R. Schreuder, R.H.M. Hermans, I.H.J.T. de Hingh, J. van der Velden, H.J. Arts, L.F.A.G. Massuger, A.G.J. Aalbers, V.J. Verwaal, J.M. Kieffer, K.K. Van de Vijver, H. van Tinteren, N.K. Aaronson, and G.S. Sonke
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
J. Spiliotis, MD, PhD, E. Halkia, MD, PhD, E. Lianos, MD, N. Kalantzi, MD, A. Grivas, MD, E. Efstathiou, MD, and S. Giassas, MD
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy
Daniel L Chan, David L Morris, Archana Rao, Terence C Chua
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients
N. Bakrin, MD, E. Cotte, MD, F. Golfier MD, PhD, F. N. Gilly, MD, PhD, G. Freyer, MD, PhD, W. Helm, MD,PhD, O. Glehen, MD, PhD, and J. M. Bereder, MD